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A pilot study for early detection of oral premalignant
diseases using oral cytology and Raman micro-spectroscopy:
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Abstract
This study demonstrates the efficacy of
Raman micro-spectroscopy of oral cytolog-
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ical samples for differentiating dysplastic,
potentially malignant lesions from those
of normal, healthy donors. Cells were collected using brush biopsy from healthy
donors (n = 20) and patients attending a
Dysplasia Clinic (n = 20). Donors were
sampled at four different sites (buccal mucosa, tongue, alveolus, gingiva), to
ensure matched normal sites for all lesions, while patient samples were taken
from clinically evident, histologically verified dysplastic lesions. Spectra were
acquired from the nucleus and cytoplasm of individual cells of all samples and
subjected to partial least squares-discriminant analysis. Discriminative sensitivities of 94% and 86% and specificity of 85% were achieved for the cytoplasm
and nucleus, respectively, largely based on lipidic contributions of dysplastic
cells. Alveolar/gingival samples were differentiated from tongue/buccal samples, indicating that anatomical site is potentially a confounding factor, while
age, gender, smoking and alcohol consumption were confirmed not to be.
KEYWORDS
oral brush biopsy cytological samples, oral potentially malignant lesions, partial least squaresdiscriminant analysis, Raman micro-spectroscopy, sensitivity and specificity
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1 | INTRODUCTION
Carcinoma of the lip and oral cavity ranks as the 18th
most common cancer in the world and the 8th most
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frequent cancer in males [1]. It has an overall 5-year survival rate of approximately 50%, due mostly to late stage
diagnosis [2]. Oral squamous cell carcinomas (OSCCs)
can either arise de novo or from potentially malignant
lesions, typically either from a leukoplakia (white patch),
erythroplakia (red patch) or erythroleukoplakia (mixed
red and white patch) [3]. Such lesions, if found to be dysplastic, have high probability of developing into malignant lesions, and are therefore clinically referred to as
potentially malignant lesions. The low rate of early diagnosis of OSCC can be partially attributed to the late recognition of such potentially malignant lesions, prior to
malignant transformation [4, 5].
The gold standard for the diagnosis of potentially
malignant lesions is biopsy and histopathological examination, in order to determine the presence and degree of
dysplasia, based on the cell morphology and tissue architecture. Furthermore, the degree of dysplasia of the
biopsy is currently regarded as the best predictor of
malignant transformation of potentially malignant
lesions [2]. Patients with oral leukoplakia, erythroplakia
and erythroleukoplakia need to be followed up long term
and often require repeated biopsies. There is, therefore,
an unmet clinical need for new technology to reduce the
need for multiple invasive tissue biopsies. As an alternative, brush-biopsy cytology is a simple, minimally invasive procedure, which is well accepted by patients [6, 7].
The oral mucosa is divided into three basic types of
epithelium, depending on the site and function: masticatory, lining and specialised epithelium [8, 9]. Gingiva and
hard palate are the sites of the oral cavity which are subject to mechanical forces associated with mastication.
These sites are covered by keratinising epithelium resembling that of the epidermis covering the skin. The dorsal
surface of the tongue is a specialised epithelium, which
can be represented as keratinised and non-keratinised
epithelium [8, 9].
The brush biopsy samples are representative of the
stratified epithelial layer of the oral mucosa which is
comprised of three layers of epithelium; basal, intermediate and superficial layer. The basal layer is the only layer
of epithelium which has dividing cells, from where cells
mature and exfoliate on the surface of the epithelium
(superficial layer) [10]. However, it is critical that the profile of the harvested sample contains the cells of interest.
In the case of mild dysplasia, histopathologically abnormal cells are present in the basal and parabasal cell layers
of the oral epithelium. As these abnormal cells are deep
inside the tissue, it is difficult to harvest them in a typical
cytopathological sample [11], which would mostly comprise of morphologically normal cells from the surface,
leading to false negative results. False-positive and falsenegative results in oral cancer diagnosis using oral
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cytology are often attributed to the fact that the cellular
sample was not collected from the full thickness of the
epithelium [11].
While assessing the potentially malignant lesion samples, cytomorphological features, such as the nuclear area
(NA), cytoplasmic area (CA), and nucleus-to-cytoplasmic
area ratio (NA/CA) are the major features that are considered in the conventional cytopathological evaluation
of exfoliated cells. It is well-known, however, that exfoliated cells from the healthy donors can differ morphologically, depending on age, gender, smoking and alcohol
consumption habits [2, 3, 12, 13]. It has previously been
reported that exfoliated cells of different genders exhibit
morphological differences due to hormonal changes in
females throughout their lifetime, from puberty to menopausal age [13]. According to an earlier report, a significant
age-related
variation
can
be
observed
morphologically in terms of NA, CA, NA/CA [13]. This
age-related variation can be ascribed to cellular senescence [14]. The renewal capacity of the basal cell layer of
normal epithelium reduces with age, resulting in the
accumulation of senescent cells. The cells which remain
for a longer duration in the oral cavity succumb to the
effect of various local environmental factors [8, 13].
It has also been reported that the keratinisation level
and nucleolar activity increases in clinically normal
mucosa of smokers [15]. Moreover, a greater percentage
of enucleated superficial cells and presence of micronuclei can be seen in the normal exfoliated cells of
smokers [15–17]. In addition, increase in nuclear size,
decrease in basal cell size and increase in number of
mitotic figures with pyknosis, karyorrhexis and karyolysis
have been reported previously due to alcohol consumption [18, 19].
Rather than relying on the morphological appearance, optical spectroscopic methods such as infrared
(IR) absorption and Raman scattering are sensitive to the
molecular composition of cells and tissue. Both techniques provide information on the vibrational frequencies of different macro-molecules (lipids, proteins,
nucleic acid and carbohydrates) and are ideally poised to
provide alternative methods for diagnosis of oral dysplasia [4]. Combining information from molecular profiles
with cytological techniques may overcome the limitations
of cytology [11]. Previously, FTIR and Raman spectroscopy has shown potential to detect oral cancer and precancerous changes using exfoliated cells [20–25].
In the present study, using the standardised protocol
of Behl et al [26] for Raman micro-spectroscopic analysis
of oral cytological samples, classification models were
constructed using partial least squares-discriminant analysis (PLS-DA) with leave one patient out cross validation
(LOPOCV) to differentiate the Raman spectra of healthy
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donors from premalignant patient samples. Concurrently,
it is also vital to test whether potential confounding factors of oral sampling site, gender, age, smoking and alcohol consumption can compromise the sensitivity and
specificity of the Raman micro-spectroscopic technique.
The rationale and the clinical aim for the study are to
develop a test that could reduce the need for multiple
biopsies for patients with potentially malignant lesions.
The implication of such potential confounding factors for
early oral cancer detection based on Raman microspectroscopy of brush biopsy samples were therefore
assessed.

2 | MATERIALS AND METHODS
2.1 | Sample collection and processing
For this pilot study, oral brush biopsy samples were collected from healthy donors (n = 20) in the FOCAS
Research Institute (in-house), Technological University
Dublin, using endocervical brushes (Aquilant Scientific,
Dublin, Ireland), and from patients (n = 20) with dysplastic oral lesions attending the Oral Mucosa Dysplasia
Clinic of the Dublin Dental University Hospital. Oral
brush biopsy cytological samples were collected from the
identified dysplastic lesion in the patient group and from
four different sites (buccal mucosa, ventral surface of the
tongue, alveolus mucosa and gingiva) in healthy donors
to ensure matched normal sites for all lesions. The
healthy donors were aged between 25 and 60 years and
patients between 40 and 90 years. The percentage of
male, female, was approximately matched (~55%, 45%).
Ethical approval was obtained from the St James' Hospital/Tallaght Hospital Joint Research Ethics Committee
(REC ref: 2013/23/05) to collect the patient samples, and
from the Dublin Institute of Technology (now TU Dublin) Research Ethics Committee (REC ref: 15/104) for the
collection of healthy donor samples. Written informed
consent was obtained from each donor and the study was
conducted in accordance with ethical principles founded
in the Declaration of Helsinki.
The healthy donors were screened before sampling by
a trained dentist who also supervised the sample collection. The oral mucosa of the healthy donors was not
biopsied. Patients were sampled by an oral medicine consultant at the Oral Mucosa Dysplasia Clinic of the Dublin
Dental University Hospital, the samples being taken from
clinically evident, histologically-proven, and dysplastic
oral lesions. All subjects were first evaluated by the clinician for the presence of histopathologically proven dysplasia and evident lesion. The brush-biopsy was a
convenience sample of the patients with the lesion taken
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when the clinician was present in the Dysplastic Clinic.
No adverse events were reported while collecting the
brush-biopsy samples. Minor bleeding was reported in
one case.
Histopathological assessment for the same patients
from whom brush biopsy cytological samples were collected was performed. The biopsies were carried out by
clinicians in the Oral Mucosa Dysplasia Clinic of the
Dublin Dental University Hospital and were submitted to
the histopathological laboratory in St. James' Hospital,
Dublin, where they were reported by an oral maxillofacial pathologist using the current WHO 2017 guidelines
for classification of oral epithelial dysplasia [27]. In the
current study, the reference test used is a histopathological assessment of potentially malignant lesion samples.
The sensitivity and specificity of the index test, that is
Raman micro-spectroscopy, have been calculated to validate the classification models using PLS-DA. The details
for the patients are given in Table 1 and the flowchart of
participants included in the study is given in Figure 1.
The standardisation of the protocol, including collection tool, sample preparation, Raman data acquisition
and processing for Raman micro-spectroscopic analysis
of healthy donors has been reported earlier [26]. Standardisation of the protocol for sample collection mainly
involves developing a method that ensures an adequate
cell number, including cells from the basal layer on the
slide to screen. To ensure proper sampling without bleeding, the collection site was vigorously rubbed (25 times)
with the endocervical brush, using moderate pressure.
This results in a good number of cells (typically
2500–6000 cells) on the slide for screening. Collected
samples were placed into ThinPrep vials and sample
slides were prepared using the ThinPrep2000 processor
forming a monolayer of cells on glass slides for analysis.
The standardised protocol was used to collect and process
patient samples and healthy donor samples.
Collected samples were placed into ThinPrep vials
and sample slides were prepared using the ThinPrep2000
processor forming a monolayer of cells on glass slides for
analysis. The standardisation protocol was used to collect
and process patient samples and healthy donor samples.

2.2 | Raman spectral acquisition
The protocol for spectral acquisition has been previously
reported for ThinPrep cervical samples [19, 20]. An
XploRA confocal Raman instrument (HORIBA
JobinYvon) was used for spectral acquisition. Manual calibration of the grating was done at 520.7 cm−1 Raman
band of crystalline silicon. Dark current measurement
and recording of the substrate and optics signal was also
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TABLE 1
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Detailed information about the patients recruited for the study

Patient
identifier

Gender

CSP001

Female

53

Alveolus

Leukoplakia

Moderate

CSP002

Male

61

Gingiva

Leukoplakia

Moderate

CSP003

Male

69

Buccal mucosa

Erythroplakia

Moderate

CSP004

Female

62

Tongue

Leukoplakia

Moderate

CSP005

Male

64

Gingiva

Leukoplakia

Moderate

CSP006

Female

67

Tongue

Leukoplakia

Mild

CSP007

Female

71

Buccal mucosa

Leukoplakia

Mild

CSP008

Female

70

Tongue

Leukoplakia

Moderate

CSP009

Female

90

Floor of mouth

Erythroplakia

Severe

CSP010

Female

49

Tongue

Leukoplakia

Severe/CIS

CSP011

Female

58

Alveolus

Leukoplakia

Mild

CSP012

Female

55

Buccal mucosa

Leukoplakia

Mild

CSP015

Male

62

Buccal mucosa

Leukoplakia

Severe

CSP016

Male

62

Buccal mucosa

Leukoplakia

Mild

CSP017

Male

72

Floor of mouth

Leukoplakia

Mild

CSP018

Female

69

Alveolus

Leukoplakia

Moderate

CSP019

Male

72

Inner lip

Leukoplakia

Mild

CSP020

Male

79

Tongue

Leukoplakia

Mild

CSP021

Female

39

Buccal mucosa

Leukoplakia

Mild

CSP022

Female

47

Buccal mucosa

Leukoplakia

Moderate

Age (y)

Oral site

performed, for data correction. As a source, a 532 nm
diode laser was focused by a 100X objective (MPlanN,
Olympus, NA = 0.9) onto the sample (~12 mW at the
focus) and the resultant Raman signals were detected
using a spectrograph with a 1200 g mm−1 grating coupled
with a CCD. Raman spectra were acquired in the 400 to
1800 cm−1 region with an integration time of 30 seconds
per spectrum and averaged over two accumulations. As it
is not known whether the nucleus or cytoplasm have
greater diagnostic potential, spectra were acquired from
the centre of the nucleus and at random from the cytoplasmic regions of the cells. Approximately 10 to 25 cells
were recorded per slide, depending on the quality of the
sample. Although a small voxel (~1 μm) is sampled each
time, randomly sampling over multiple (10-25) cells
means that the distribution of samplings effectively represents the variability across the cellular region [28–30].

2.3 | Raman spectral processing and
analysis
All the data processing and analyses were carried out using
Matlab (Mathworks, USA), PLS-Toolbox (Eigenvector
Research, Inc) using in-house algorithms.

Clinical features
of lesion

Histopathological
assessment (WHO guidelines)

The glass spectral interference with the biological
Raman signals was removed using the extended multiplicative signal correction (EMSC), as described by Kerr et al
[31]. The EMSC algorithm also includes a polynomial term,
and order n = 5, was used to correct the baseline of the
Raman spectral dataset. After glass correction, the datasets
for nucleus and cytoplasm were subjected to smoothing
(Savitzky-Golay, order = 5; window = 13), outlier removal
using Grubb test [32] and vector normalisation.
Subsequently, pre-processed spectra of nucleus and
cytoplasm were subjected to PLS-DA. PLS-DA was used
to build models in order to train the dataset. PLS-DA is a
supervised form of multivariate analysis which works as
a linear classifier that aims to maximise the variance
between groups and minimise the variance within
groups. The loadings of the discriminate, that is latent
variables (LVs) can be plotted to give more information
on the source of the variance [33].
Cross validation of PLS-DA classification is carried
out in order to avoid over or under-fitting the model due
to inappropriate selection of the components used, and
secondly to determine the prediction error of the model.
In leave one patient out cross validation, (LOPOCV) or
leave one spectrum out cross validation (LOOCV), observations of one patient/spectrum are excluded, one at a
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F I G U R E 1 Flowchart of participants.
Index test = Raman micro-spectroscopic test;
reference test = histopathological assessment

time, from the training set and the resulting model is
evaluated by using the left out observations as tests. The
procedure is repeated until all patients/spectra have been
left out once and the average performance across all
interactions is considered the performance of the classification model [34]. The one-way analysis of variance
(ANOVA) was employed for calculating the significance
of the outcomes for PLS-DA scores of healthy donors and
patient samples in terms of P-values [35, 36].

3 | R ES U L T S A N D D I S C U S S I O N
In the present study, brush biopsy cytological samples
were collected from four sites in healthy donors (n = 20)
and from patients (n = 20) with identified leukoplakia,
erythroplakia or erythroleukoplakia, showing mild, moderate or severe dysplasia on histological analysis.
Representative Papanicolaou (Pap) stained oral cytological samples can be seen in Figure 2. The samples
obtained from mild and moderately dysplastic lesions
mainly consisted of morphologically normal appearing
cells, as shown in Figure 2A,B. However, increased numbers of abnormal cells, along with normal appearing
cells, were observed in the samples from severely dysplastic lesions. In Figure 1C, the red arrow highlights an
example of an abnormal cell in a severely dysplastic
lesion. Raman spectra were acquired randomly from the
samples, of morphologically normal and abnormal cells,
from lesions reported as mild, moderate and severe
dysplasia.
The mean spectra of cytoplasmic and nuclear regions
of the cells from patients with potentially malignant

lesions and healthy donors show similar spectral profiles,
as can be seen in Figure 3A,B. The shading of the spectra
indicates the SD. To better elucidate the subtle spectral
differences between the healthy donor and patient samples, the difference spectra were also computed for both
cytoplasmic and nuclear datasets (Figure 3A,B), subtracting the mean spectrum of patient samples from the
mean spectrum of healthy donor samples. In Figure 3A,
B, all positive bands correspond to healthy donors, while
the negative bands were from the patient samples.
Table 2 illustrates the major Raman band assignments
[37–42] used in the present study of healthy donors and
patients with potentially malignant lesions. In the case of
cytoplasm, protein (636, 845, 997, 1237, 1361, 1597 and
1645 cm−1) and lipid (1437 cm−1) derived bands were
observed to be prominent for healthy donor samples,
whereas, for patient samples, nucleic acid (721, 780,
1180 cm−1) and lipid (1060, 1135, 1300, 1417 and
1745 cm−1) bands were observed. In the nuclear dataset,
prominent protein (636, 842, 994, 1234, 1361, 1482, 1575,
1665 cm−1) and nucleic acid (780, 1482, 1575 cm−1)
bands were observed for healthy donors, lipid (712, 938,
1060, 1300, 1745 cm−1) and protein (938, 1460,
1648 cm−1) bands for patient samples. A predictive model
based on the Raman micro-spectroscopic analysis was
developed using PLS-DA with LOPOCV. The score plots
of PLS-DA indicated that both LV1 and LV2 contribute
to the differentiation of patient and healthy volunteer
samples for both cytoplasmic (Supporting Information
Figure S1) and nuclear (Figure 4A) datasets.
In the case of PLS-DA of the nuclear dataset
(Figure 4B), negative bands of the LV1 loading,
corresponding to samples from potentially malignant
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F I G U R E 2 Representative Pap stained oral cytological sample (20×) from lesions reported as A, mild; B, moderate and C, severe
dysplasia. In C, the red arrow highlights an example of an abnormal cell

F I G U R E 3 Mean and difference spectra of healthy donors (normal) and patients (lesions) for A, cytoplasmic and B, nuclear dataset.
Shading denotes SD. Note: the y-scale of the difference spectrum is different to that of the mean spectra

lesions, were of lipids (602, 705. 1132, 1155, 1300,
1750 cm−1), whereas prominent nucleic acid bands
(726, 780, 828, 1094, 1369, 1485, 1572 cm−1) were

observed in the cells from healthy donors on the positive
bands of LV1 loading. The loading of LV2 showed a similar prominence of lipidic (1065, 1300, 1745 cm−1) features
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Major Raman band positions and assignments [38–43] in oral cytology for healthy donors and patients

Biomolecule

Raman bands (cm−1)

Proteins

521, 534, 571, 628-662, 830-835, 859, 890, 921, 935, 952, 963, 994-1008, 1028, 1040, 1163, 1177,
1197, 1200, 1228, 1234, 1259, 1273, 1361, 1454, 1460, 1470, 1532, 1544, 1600, 1648, 1655-80

Lipids

602, 705, 712, 715, 1060-1065, 1130-1135, 1146, 1155, 1300, 1392, 1417, 1437, 1465, 1642, 1673, 1730-1760

Nucleic acids

720-730, 780-785, 1090-1095, 1180, 1296, 1346, 1361, 1369, 1482-1485, 1572-1578

F I G U R E 4 PLS-DA predictive model for nucleus (normal vs lesion). A, Score plot; B, latent variable 1; C, latent variable 2; D,
predictive model and E, confusion matrix

for the patient samples. In the case of patient samples,
bands located at 1060, 1300, and 1750 cm−1 in LV1 and
LV2 are consistent with the observations of the difference
spectrum of Figure 3B, whereas for healthy donor samples, the 1437 cm-1 band in LV2 is also prominent in the
difference spectrum. The predicted probability of the cellular spectroscopic measurement being assigned as normal or dysplastic is shown in the PLS-DA model with
LOPOCV (Figure 4C). The confusion matrix of the model
indicates 86% sensitivity (95% CI 82%-89%) and 85% specificity (95% CI 80%-88%) for the nuclear dataset
(Figure 4D). Similarly, in the case of cytoplasm, potentially malignant lesion samples were found to be relatively rich in lipids (LV1; 602, 1130, 1465, 1750 cm−1 and
LV2 1065, 1437, 1740 cm−1), as shown in Supporting
Information Figure S1b. Yet again, in the case of patient
samples, bands located at 1060, 1300, and 1750 cm-1 of
LV1 and LV2 are consistent with the observations of the
difference spectrum, whereas unlike the nucleus, in the
case of the cytoplasm, the 1437 cm-1 band is present in

patient samples of LV2 instead of healthy donors. The
confusion matrix (Supporting Information Figure S1d) of
the model indicates 94% sensitivity (95% CI 91%-96%)
and 85% specificity (95% CI 80%-88%).
Typically, a cytopathological assessment is based
on morphological differences between healthy and
patient samples. In certain cases, such as mild dysplasia, cellular changes occur near the basal layer, deep
within the epithelium, which makes it difficult to harvest the abnormal cells in typical cytological samples.
This can lead to false negative results, which reduce
the sensitivity to as low as 69% [43]. In this pilot study,
Raman spectra were acquired from morphologically
normal and abnormal cells from patients with mild,
moderate and severely dysplastic lesions, and discriminative sensitivity of 94% and 86% was achieved for
both the cytoplasmic and the nuclear datasets respectively. Hence, successful classification models for
patient samples and healthy donor samples could be
developed.
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The prominence of lipidic features in both the mean
difference spectra and the discriminating LVs suggests
altered lipid metabolisation pathways in the patient samples compared to the healthy donor samples and it may
be explained by reprogramming of lipids during disease
progression to fulfil the increased energy requirements
[44] Notably, however, for both the cytoplasmic and
nuclear regions, the lipid ester band at 1745 cm−1 is not
so prominent in the multivariate discriminant analysis as
it appears in the difference of the mean spectra in
Figure 3. It is well known that, with increasing severity
of dysplasia or cancer, the lipidic content of cells
increases in the cytoplasm as well as in the nucleus [44,
45]. This can be attributed to the fact that, during cell
division, cells need energy, and this requirement is fulfilled by upregulating lipid metabolism within the cell
[44, 45]. In our study, increased lipidic content is the
dominant differentiating factor of potentially malignant
lesion samples for both the cytoplasmic and nuclear
datasets. Furthermore, the results also suggest that morphologically normal cells of potentially malignant lesions
are not biochemically normal and have the potential to
transform into abnormal cells. Raman microspectroscopy can detect these subtle changes which are
not as yet manifest morphologically. In this way, it can
compensate for the fact that cytopathological sampling
may not harvest dysplastic cells at or near the basal layer.
Subsequently, oral site as a confounding factor was
tested in order to assess its influence on the PLS-DA predictive model. To facilitate the understanding of oral site
as a confounding factor, it has been depicted in the predictive model for both cytoplasm and nuclear datasets
respectively, as shown in Supporting Information
Figure S2 and Figure 5. The four different sites; gingiva,
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alveolar, buccal mucosa and ventral surface of the tongue
were considered, with the aim of understanding the
influence of different anatomical sites on the analysis
protocol for healthy donors and patients respectively for
each site (Supporting Information Figure S2b and
Figure 5B). It was observed that gingival and alveolar
spectra from healthy donors were misclassified with
patient samples for both cytoplasmic as well as the
nuclear datasets (Supporting Information Figure S2b and
Figure 5B). Even though, the P values were found to be
less than .00001 for the scores of PLS-DA (cytoplasm and
nucleus) for healthy donors and patient samples using
one-way ANOVA, due to misclassification of gingival and
alveolar spectra with patient samples the overall efficiency of the model has been reduced which can be seen
in Supporting Information Figure S2 and Figure 5.
In order to account for the influence of different sites
on the predictive model, gingiva/alveolus mucosa samples (n = 3) were removed from the overall dataset. Using
only the remaining buccal mucosa/tongues samples,
PLS-DA classification models for healthy donors and
patients were developed which are shown in Supporting
Information Figure S3 for the cytoplasmic dataset and
Figure 6 for the nuclear dataset. In both, it is possible to
distinguish healthy donors from patient samples
according to LV 1 and LV 2, which can be seen in the
scores plot of PLS-DA (Supporting Information
Figure S3a and 6a). The LV1 and LV2 for cytoplasm as
well as nucleus respectively were similar to those in
Supporting Information Figure S1 and Figure 4. In the
case of PLS-DA of the nuclear dataset (Figure 6B), negative bands at of LV1, corresponding to potentially malignant lesions, were of lipids [39, 40], whereas prominent
DNA bands were observed in the cells from healthy

F I G U R E 5 A, PLS-DA score plot for nuclear spectra from healthy donors (normal) vs patients (lesions). B, Depicting anatomical sites.
(One-way ANOVA, P < .00001 for both LV1 and LV2)

BEHL ET AL.

donors as the positive bands [39, 40]. The lipid bands
were also observed in LV2 of negative bands
corresponding to the patient samples. The confusion
matrix of the model indicated 97% sensitivity/specificity
for the cytoplasmic dataset (Supporting Information
Figure S3e), whereas 94% sensitivity and 95% specificity
was achieved in the case of the nuclear dataset
(Figure 6E). For the cytoplasm, negative bands of LV1
loading corresponding to potentially malignant lesion
samples were found to be rich in lipids and DNA bands
[39, 40], as shown in Supporting Information
Figure S3b. It was also observed that the positive bands
of LV1, corresponding to healthy donors, were predominantly of proteins [39, 40], as can be seen in Supporting
Information Figure S3b. Similarly, lipids bands were
observed in patient samples on LV2. This has suggested
that the model can be effectively improved by developing
two separate models for gingiva/alveolus and buccal
mucosa/tongue samples. Therefore, it has been concluded that, for the future studies, two separate models
will be developed based on difference in oral sites.
After confirming oral sites as a confounding factor,
the influence of various other potential confounding factors such as gender, age, smoking and alcohol consumption were assessed for their influence on the buccal/
tongue PLS-DA classification model for healthy donors
and patients. Firstly, gender is illustrated in the scores
plot of the PLS-DA model for cytoplasm and nucleus
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(Supporting Information Figure S4a and Figure 7A) using
six females and nine males for healthy donors and nine
females and six males for patient samples. Secondly, age
profile is shown in the classification model of the potentially malignant lesion samples (50+ years (n = 13) and
under 50 years (n = 2)) and healthy donors (20–30 years
(n = 10), 30–50 years (n = 4), 50+ years (n = 1)) in
Supporting Information Figure S4b and Figure 7B. The
third potential confounding factor that was considered is
smoking, which is depicted in the scores plot of the PLSDA scatter plot (Supporting Information Figure S4c and
Figure 7C) for patient samples (smokers (n = 3), exsmokers (n = 6), non-smokers (n = 6)) and healthy
(smokers (n = 4), non-smokers (n = 11)). Finally, alcohol
consumption was examined as the fourth potential confounding factor, shown in Supporting Information
Figure S4d and Figure 7D, using patient samples
(no alcohol (n = 5) and alcohol consumption (n = 10))
and healthy donor samples (no alcohol (n = 3) and alcohol consumption (n = 12)). From the scores plot of the
PLS-DA (Supporting Information Figure S4 and Figure 7)
of patients with potentially malignant lesions and healthy
donors, it is clear that, irrespective of gender, age,
smoking and alcohol consumption, it is possible to distinguish healthy donors from patient samples according to
LV 1 for the cytoplasmic as well as the nuclear dataset. A
one-way ANOVA test indicated P values lower than .0001
for the scores of healthy donors and patient samples

F I G U R E 6 PLS-DA predictive model for nucleus spectra from buccal mucosa/tongue (normal vs lesion). A, Score plot; B, latent
variable 1; C, latent variable 2; D, predictive model and E, confusion matrix
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F I G U R E 7 PLS-DA predictive model for nucleus spectra for healthy donors (normal) vs patient samples (lesion). A, Score plot
gender; B, score plot age; C, score plot smoking and D, score plot alcohol consumption. (One-way ANOVA, P < .00001)

(in Supporting Information Figure S4 and Figure 7).
Since the overall sensitivity of the model has been
improved after the removal of the gingival and alveolar
samples, it was concluded that gender, age, smoking or
alcohol consumption habits do not confound the Ramanbased classification model.
The result suggests that any gender, age, smoking
and alcohol consumption dependent morphological differences were not reflected at the molecular level and
were not manifest in the Raman spectral profiles. The
samples for confounding factors such as gender,
smoking and alcohol consumption were approximately
matched. However, the age distribution was, to a certain
extent, biased towards younger donors. Nevertheless,
this age distribution was not seen to be a factor in the
spectral profile of normal samples. Thus, it can be concluded that the healthy donor or patient datasets are not
influenced by gender, age, smoking or alcohol consumption, while using Raman micro-spectroscopy as a diagnostic technique.

4 | CONCLUSION
Raman micro-spectroscopy was found to be able to successfully discriminate oral cytology samples from patients
with potentially malignant lesions from those of healthy
donors with 94% and 86% sensitivity, based on analysis of
both cytoplasmic and nuclear regions. Morphologically
normal cells within potentially malignant lesions were
identified as abnormal due to the biochemical differences
manifest in their Raman spectroscopic profiles. Thus,
Raman micro-spectroscopy can detect subtle changes in
cells that could be falsely diagnosed as normal based on
morphology alone. Hence, this study has shown that the
limitations associated with the cytopathological assessment of oral dysplastic lesions could be successfully overcome by Raman micro-spectroscopy, which identifies
biochemical differences in the morphologically normal
cells within these dysplastic oral lesions.
Furthermore, even though for the present study the
spectra were acquired from the morphologically normal
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cells of potentially malignant lesion samples, all the
patient samples which were included in the study were
from histopathologically confirmed dysplastic lesion samples. Thus, through our study, the dysplastic patient samples could be accurately differentiated from nondysplastic healthy donor samples using Raman microspectroscopy and brush biopsy samples. This, in turn, has
implications in clinical practice to reduce the need for
multiple biopsies for screening the presence of disease. In
future, a study will be carried out for histologically classified dysplastic lesions versus non-dysplastic lesions.
It was, however, observed that the Raman spectral
profiles of cells from gingiva/alveolus sites were distinctively different from those from the buccal mucosa/ventral surface of the tongue in healthy donors. Moreover, it
was also observed that Raman spectra from gingiva/alveolus mucosa samples from healthy volunteers were misclassified with potentially malignant lesion samples.
Thus, it was concluded that oral site is a confounding factor for diagnostic applications and can have an impact on
classification models. Anatomical selectivity can clearly
be controlled in the clinical sampling protocol, and thus
is not a significant impediment for the further development of the label free analysis technique for screening of
potentially malignant lesions.
Furthermore, this study has indicated that although
morphological changes have been reported due to differences in gender, age, smoking, and alcohol consumption
in the cells of healthy donors, these changes are not
manifested at the molecular level to be detected by
Raman micro-spectroscopy. Therefore, it has been concluded that gender, age, smoking and alcohol have no
influence on developing classification models for healthy
donors and patients using Raman micro-spectroscopy.
At present, the adoption of Raman spectroscopy as a
diagnostic method to detect degrees of dysplasia in oral
mucosal cells is at the “proof of concept” stage, but
results are very encouraging. In the future, this study will
be carried out with a larger number of samples and it
should be possible to develop the technique, such that it
can be used in vivo, with real-time data analysis. The
technique represents a potentially powerful tool to assist
in directing the clinician to the most appropriate biopsy
site for extensive leukoplakic lesions (Raman-directed
biopsy). It could also be an intra-operative surgical aid in
locating the excision margin [46] of tumours, so all dysplastic tissue is removed where clinically feasible.
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